Table diabetes_ndcs_wac_increases_5_year

Table: diabetes_ndcs_wac_increases_5_year_history , manufacturer_name like M*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

year_str	oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006007861	JANUMET XR 50 mg-500 mg Tablets 60	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006007862	JANUMET XR 50 mg-500 mg Tablets 180	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2 )the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006007882	JANUMET XR 50 mg-500 mg Tablets 1000	01/03/2020	370.00	7890.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008061	JANUMET XR 50 mg-1000 mg Tablets 60	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008062	JANUMET XR 50 mg-1000 mg Tablets 180	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008082	JANUMET XR 50 mg-1000 mg Tablets 1000	01/03/2020	370.00	7890.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008131	JANUMET XR 100 mg-1000 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008154	JANUMET XR 100 mg-1000 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008182	JANUMET XR 100 mg-1000 mg Tablets 1000	01/03/2020	740.00	15780.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006011228	JANUVIA 50 mg Tablets 100	01/03/2020	74.00	1578.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006011231	JANUVIA 50 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006011254	JANUVIA 50 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006022128	JANUVIA 25 mg Tablets 100	01/03/2020	74.00	1578.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006022131	JANUVIA 25 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006022154	JANUVIA 25 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006027728	JANUVIA 100 mg Tablets 100	01/03/2020	74.00	1578.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006027731	JANUVIA 100 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006027754	JANUVIA 100 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006027782	JANUVIA 100 mg Tablets 1000	01/03/2020	740.00	15780.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057561	JANUMET 50 mg-500 mg Tablets 60	01/03/2020	22.20	473.40	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057562	JANUMET 50 mg-500 mg Tablets 180	01/03/2020	66.60	1420.20	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057582	JANUMET 50 mg-500 mg Tablets 1000	01/03/2020	370.00	7890.00	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057761	JANUMET 50 mg-1000 mg Tablets 60	01/03/2020	22.20	473.40	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057762	JANUMET 50 mg-1000 mg Tablets 180	01/03/2020	66.60	1420.20	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057782	JANUMET 50 mg-1000 mg Tablets 1000	01/03/2020	370.00	7890.00	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.